High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is
the most common and deadliest type of ovarian cancer. HGSC appears to arise from the …

The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two
decades ago helped set in motion an avalanche of research exploring how genomic …

Purpose The purposes of this study were to estimate the reduction in risk of ovarian,
fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after …

BACKGROUND Breast cancer (BC) disparities may widen with genomic advances. The
authors compared non‐Hispanic white (NHW), black, and Hispanic BC survivors for 1) …

Background Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian
cancer. In the current study, we report on uptake of cancer screening and risk-reduction …

Background Preventive therapy is a risk reduction option for women who have an increased
risk of breast cancer. The effectiveness of preventive therapy to reduce breast cancer …

Background Recent progress in understanding the genetic basis of breast cancer and
widely publicized reports of celebrities undergoing risk‐reducing mastectomy (RRM) have …

Importance Low-cost sequencing of multiple genes is increasingly available for cancer risk
assessment. Little is known about uptake or outcomes of multiple-gene sequencing after …

Background Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated
risk of developing ovarian cancer. The aim of the meta-analysis is to clarify the role of risk …

Importance Prophylactic bilateral salpingo-oophorectomy is recommended
forBRCA1mutation carriers to prevent ovarian cancer. Whether or not hormone replacement …